Hub · Peptide Quality & Verification
TB-500 vs thymosin beta-4: is TB-500 the same molecule?
TB-500 is not the same molecule as thymosin beta-4. Thymosin beta-4 is a natural protein 43 amino acids long (Low et al., 1981). Amino acids are the small units that proteins are built from. In the papers that define it, TB-500 is a synthetic fragment. A fragment is a short piece of that chain. Here it is made in a laboratory. It has seven amino acids, LKKTETQ. It has an acetyl group on the first one. An acetyl group is a small chemical tag (Ho et al., 2012).
01Same molecule?Contents
Your cells keep their shape with an inner scaffold of thread-like protein. The threads are built from a protein called actin. UniProt is a public protein database. It records thymosin beta-4 as a binder of single actin units (UniProt P62328). A 2010 review calls it the major actin-sequestering molecule in cells with a nucleus. That means it holds actin units in reserve (Sosne et al., 2010).
This page is part of the peptide quality & verification hub. There, a peptide means a short chain of amino acids. The page asks one naming question. When someone writes TB-500, which molecule is meant? Research papers that give an exact amino-acid sequence answer it. A sequence is the order of units along a chain.
Guidepeptide quality & verification hubHow research peptides are tested and verified: purity methods, certificates of analysis, batch traceability, and what each document can and cannot tell you.
Key facts
| Parent protein | Thymosin beta-4, 43 amino acids long (Low et al., 1981) |
|---|---|
| TB-500 as defined in two papers | Ac-LKKTETQ, where Ac- is the acetyl tag; 7 amino acids (Ho et al., 2012; Esposito et al., 2012) |
| Fragment position | Positions 17 to 23 of the 43 (Sosne et al., 2010) |
| Protein record | UniProt P62328, an entry in a public protein database |
| Evidence used here | Identity and sequence findings only; no effect findings used |
Is TB-500 the same as thymosin beta-4?
TB-500 is not the same as thymosin beta-4 in the papers that define the two. Thymosin beta-4 is a protein of 43 amino acids (Low et al., 1981). Each letter in its sequence stands for one unit of the chain. Two laboratory-testing papers define TB-500 as the seven-unit peptide Ac-LKKTETQ. It sits at positions 17 to 23 of that protein. It has an acetyl group added to its first unit (Esposito et al., 2012; Ho et al., 2012). A fragment is a short piece of a longer molecule. So TB-500 is a piece of thymosin beta-4, not the whole protein.
What is full-length thymosin beta-4?
Thymosin beta-4 is a natural protein of 43 amino acids. It was sequenced from calf thymus in 1981 (Low et al., 1981). The thymus is a small gland in the chest. UniProt lists the human sequence in groups of ten letters: SDKPDMAEIE KFDKSKLKKT ETQEKNPLPS KETIEQEKQA GES. It leaves out the starting amino acid, methionine, which the cell removes. It records an acetylated serine at the first position (UniProt P62328). Serine is an amino acid. The same entry says the protein binds and sequesters actin monomers. That means it holds single actin units and stops them joining into threads. A 2010 review names the stretch LKKTETQ, at positions 17 to 23, as the central actin-binding part of the protein (Sosne et al., 2010).
The sequence is a string of letters, so it reads like a sentence. The first four letters, SDKP, form a different named part, Ac-SDKP. TB-500 does not include it (Sosne et al., 2010).
What is the TB-500 fragment, and how do papers identify it?
A 2012 paper on testing horse samples describes TB-500 as a veterinary preparation. That is a product made for animal use. Its key ingredient is LKKTETQ with an artificial acetyl group on its first end (Ho et al., 2012). A second 2012 paper detected Ac-LKKTETQ inside TB-500. It used high-performance liquid chromatography with high-resolution mass spectrometry. That method separates a mixture and weighs each molecule. The paper also made the fragment by chemical synthesis (Esposito et al., 2012). In both papers the name TB-500 is tied to a stated sequence and a stated acetyl tag. That is what makes the identity checkable.
The name alone does not settle identity. The letters and the tag are what a laboratory can test. The TB-500 research guide collects the published studies in one place.
GuideTB-500 research guideA plain-English guide to TB-500: the actin-binding fragment of thymosin beta-4, what's been studied, and why it isn't the same as the full protein.
Evidence limits
Does the name TB-500 always mean this exact fragment?
No source on this page shows that every product or study called TB-500 contains Ac-LKKTETQ. Ho et al. (2012) and Esposito et al. (2012) each name the sequence and the acetyl tag for the material they examined. That is evidence about those preparations only. A 2003 animal study abstract names the seven-unit peptide LKKTETQ. It does not say whether the peptide carried an acetyl tag (Philp et al., 2003). So that abstract alone cannot be matched to Ac-LKKTETQ. A label, a catalogue name or a paper that says TB-500 without the sequence and the tag leaves the identity open.
A researcher holding paperwork can ask whether a batch record names the sequence and the tag. How to read a certificate of analysis covers the fields. What a batch or lot number lets a researcher verify covers the code that ties a vial to its record. The catalogue entry is TB-500 reference material.
GuideHow to read a certificate of analysisWhat a certificate of analysis shows: its fields, purpose and layout, how it differs from a safety data sheet, what purity and identity numbers prove, and where the paperwork stops.
GuideWhat a batch or lot number lets a researcher verifyA batch or lot number identifies one production run. What that code lets a researcher check, what it ties together, and where its verifying power stops.
Research use onlyTB-500In stockTB-500 reference material
Comparison
Each row compares one checkable property. Every cell names its source. No row describes effects.
| Property | Thymosin beta-4 (full length) | TB-500 (as defined in the papers) |
|---|---|---|
| Length | 43 amino acids (Low et al., 1981) | 7 amino acids (Ho et al., 2012) |
| Position | Positions 1 to 43 (Sosne et al., 2010) | Positions 17 to 23 of the 43 (Ho et al., 2012) |
| Sequence in one-letter codes (one letter per amino acid) | SDKPDMAEIE KFDKSKLKKT ETQEKNPLPS KETIEQEKQA GES (UniProt P62328) | LKKTETQ (Ho et al., 2012) |
| Acetyl tag | On the first unit, serine (Low et al., 1981; UniProt P62328) | On the first unit, the amino acid leucine, added artificially (Ho et al., 2012) |
| Origin | Natural protein, sequenced from calf thymus (Low et al., 1981) | Synthetic version of the fragment (Ho et al., 2012) |
| First four positions | Hold the named part Ac-SDKP (Sosne et al., 2010) | Lie outside the fragment, which spans positions 17 to 23 (Ho et al., 2012) |
FAQ
Is TB-500 a fragment of thymosin beta-4?
TB-500 is described as a fragment of thymosin beta-4. It is the seven-amino-acid stretch at positions 17 to 23, with an added acetyl tag (Ho et al., 2012; Sosne et al., 2010).
Is thymosin beta-4 the same as Ac-SDKP?
Thymosin beta-4 is not the same as Ac-SDKP. Ac-SDKP is a four-amino-acid part at positions 1 to 4 of the protein. UniProt lists it as a peptide contained in thymosin beta-4 (Sosne et al., 2010; UniProt P62328). TB-500 covers positions 17 to 23 and does not include it (Ho et al., 2012).
Does Australian law list TB-500 and thymosin beta-4 as the same thing?
Australian law lists them separately. The Poisons Standard is the national list of controlled medicines and poisons. It names TB-500 and thymosin beta 4 (thymosin β4) as two entries. Each is in Schedule 4 (prescription-only medicines) and Appendix D, clause 5 (poisons that must not be possessed without authority). The source is the Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026, F2026L01327, checked 1 October 2026 UTC (universal time). Each entry is a name without a description.
More in this hub
GuidePeptide Quality & VerificationHow research peptides are tested and verified: purity methods, certificates of analysis, batch traceability, and what each document can and cannot tell you.
GuideWhich peptide company is the most trusted?What regulator letters, batch tests and business records can show about peptide companies. Learn why company size cannot settle trust.
GuideHow to read a certificate of analysis (COA)What a certificate of analysis shows: its fields, purpose and layout, how it differs from a safety data sheet, what purity and identity numbers prove, and where the paperwork stops.
GuideHow to check a peptide certificate of analysis is genuineA field-by-field checklist for a peptide certificate of analysis: match the batch, confirm the laboratory, read the test scope, and see what each check can and cannot show.
GuideHow to check an Australian peptide supplier is legitimateTen checks for an Australian research peptide supplier: business identity, contact details, batch documents, test scope, payment records, handling and regulatory warnings.
GuideWhat research grade actually meansResearch grade is a catalogue phrase, not a published standard. What named grades like ACS and USP are, and what For Research Use Only does not mean.
GuideWhat a batch or lot number lets a researcher verifyA batch or lot number identifies one production run. What that code lets a researcher check, what it ties together, and where its verifying power stops.
GuideCJC-1295 with DAC vs without DAC: what is the difference?CJC-1295 with DAC and without DAC are two different peptides. Side-by-side sequence, half-life literature and registry numbers, and what modified GRF(1-29) means.
GuideSelank vs Semax: are they the same peptide?Selank and Semax are two different seven-amino-acid peptides that share a Pro-Gly-Pro ending. A position-by-position sequence table, origins, what studies say about which is better, DSIP, and the limits of comparing studies.
GuideIs NAD+ a peptide?NAD+ is a coenzyme made of two nucleotides, not a peptide. What the PubChem, ChEBI and wwPDB records show about its structure.
GuideHow mass spectrometry confirms peptide identityHow mass spectrometry confirms peptide identity: what a matching mass shows, how fragmentation reads the sequence, and why identical masses call for a second test.
GuideHow HPLC purity is measured for peptides
GuideEndotoxin, sterility and purity: three different testsWhat an endotoxin test, a sterility test and a purity test each measure, and which of the three the 14 lab reports on file at Form Laboratories document.
GuideBioburden vs endotoxin testing: what each one measuresBioburden testing counts living microorganisms. Endotoxin testing looks for a bacterial cell-wall molecule. Why one cannot stand in for the other, with ISO 11737-1 and FDA guidance cited.
GuideNet peptide content: what it is and how it is measuredNet peptide content is the share of a freeze-dried peptide's mass that is the peptide itself. How amino acid analysis, nitrogen analysis and mass balance measure it, and why it differs from HPLC purity.
GuidePeptide TFA salt: what trifluoroacetate is and how it is measuredA peptide TFA salt carries trifluoroacetate as its counterion. Why synthetic peptides often have it, how it is measured on its own, and why an HPLC purity figure does not show the salt form.
GuideTypes of peptide impurities: sequence-related, degradation and non-peptideThe main categories of impurity in a synthetic peptide: sequence-related, degradation products and non-peptide material, and why different tests look for different categories. Cited to the EMA guideline.
GuideWhat does a peptide cleavage predictor measure?What peptide cleavage predictors estimate from an amino acid sequence, what cut-site scores mean, and why a computer prediction needs separate lab evidence.
GuideWhat is peptide mass fingerprinting, and what can it identify?Peptide mass, mass-to-charge ratio and mass fingerprinting explained: what a database match can identify, why sequence matters, and what purity needs.
Citations
5 sourcesLow TL, Hu SK, Goldstein AL. Proceedings of the National Academy of Sciences. 1981;78(2):1162-1166.
doi:10.1073/pnas.78.2.1162Sosne G, Qiu P, Goldstein AL, Wheater M. FASEB Journal. 2010;24(7):2144-2151.
doi:10.1096/fj.09-142307- Sourcedoi:10.1096/fj.09-142307
Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Journal of Chromatography A. 2012;1265:57-69.
doi:10.1016/j.chroma.2012.09.043Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Drug Testing and Analysis. 2012;4(9):733-738.
doi:10.1002/dta.1402- Sourcedoi:10.1002/dta.1402
Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Wound Repair and Regeneration. 2003;11(1):19-24.
doi:10.1046/j.1524-475x.2003.11105.x
Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
